BeOne Medicines (formerly BeiGene)
↗Cambridge, Massachusetts, United States (corporate); Basel, Switzerland (post-redomiciliation May 2025)
BeOne Medicines (formerly BeiGene, Ltd.) is a global oncology company discovering and developing innovative cancer treatments designed to be more accessible and affordable for patients worldwide. The company operates with one of the largest oncology research teams globally and distinguishes itself through a CRO-free (contract research organization-free) strategy, conducting global clinical trials with its own internal team. Founded in 2010 and headquartered in Cambridge, Massachusetts with a global presence across six continents in over 45 countries, BeOne Medicines focuses on hematologic and solid tumors with a diverse portfolio of small molecules, monoclonal antibodies, antibody-drug conjugates, and emerging cell and gene therapies. The company rebranded from BeiGene to BeOne Medicines in November 2024 and changed its Nasdaq ticker to 'ONC' in January 2025.
CLASSIFICATION
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$4.9B-$5.3B (2025 guidance)
Founded:2010
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:Amgen (20.5% stake acquired 2019 for $2.7B)
STOCK
Exchange:NASDAQ
Ticker:ONC (formerly BGNE)
Market Cap:$19.7B
PIPELINE
Stage:Phase 1-3 and Commercial
Lead Drug Stage:Commercial (Brukinsa/zanubrutinib and Tevimbra/tislelizumab)
Modalities:Small molecule, Monoclonal antibody (mAb), Antibody-drug conjugate (ADC), BTK inhibitor, PD-1 inhibitor, Cell therapy, Gene therapy, RNA therapy, CDK inhibitor, KRAS inhibitor, PRMT5 inhibitor
Active Trials:50
Trial Phases:Phase 1: 15 | Phase 2: 20 | Phase 3: 12 | Phase 4: 3
FDA Approvals:6
EMA Approvals:1
CORPORATE STRUCTURE
Key Partnerships:Amgen (strategic collaboration for China expansion; Amgen holds 20.5% equity stake), Novartis (tislelizumab in-licensing agreement), DualityBio (ADC partnership for solid tumors), Ensem Therapeutics (CDK2 inhibitor license), Takeda (oncology partnerships), Legend Biotech (oncology collaborations)
COMPETITION
Position:Challenger
Competitors:Roche, AstraZeneca, Novartis, Regeneron Pharmaceuticals, Jazz Pharmaceuticals, Takeda Pharmaceutical, Legend Biotech, Innovent Biologics +2 more
LEADERSHIP
Key Executives:
John V. Oyler - Chief Executive Officer & Founder
Xiaodong Wang - Co-Founder & Chairman of Scientific Advisory Board
Xiaobin Wu - President, Chief Operating Officer & General Manager of China
Ji Li, Ph.D. - Executive Vice President & Global Head of Business Development
Scientific Founders:Xiaodong Wang
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BeOne Medicines (formerly BeiGene). The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.